Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Entrada Therapeutics Reports Third Quarter 2026 Financial Results
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Our Platform
Our proprietary EEV™ Platform has the potential to reach and engage previously inaccessible and undruggable disease-causing targets within cells.
Our Clinical Studies
At Entrada we are united in our mission to treat devastating diseases with intracellular therapeutics — including Duchenne muscular dystrophy.
Our Pipeline
Our EEV™ Platform is highly versatile and modular, offering broad potential across therapeutic areas. We are developing potential treatments spanning discovery to clinical-stage across retinal, neuromuscular and metabolic diseases, and this is just the beginning.
Life at Entrada
Innovation isn’t easy, and we’re up for the challenge. Are you?